The FDA clears CERo Theraputics' investigational new drug application (IND) of its lead compound, CER 1236, for Phase 1 clinical trials in acute myelogenous leukemia (AML)
CERo Therapeutics Holdings, Inc. announces that the FDA has cleared the Company’s Investigational New Drug Application (IND) for Phase I clinical trials of its lead compound, CER 1236, in acute myelogenous leukemia (AML)
Interim CEO Chris Ehrlich commented, “Following our productive discussions with FDA, we look forward to initiating our first in-human trial of CER 1236 in AML. We believe our lead compound offers a novel and powerful approach in treating cancer and will explore its differentiated attributes in the upcoming clinical trial in patients with one of the deadliest of all cancers, AML. To be sure, I want to thank the entire CERo team for bringing CER 1236 to this pivotal point in its development, a very important milestone for all of us. Now this team will turn its attention to expeditiously deploying our resources in anticipation of what we believe will be a first quarter 2025 start for our Phase I trial, and we look forward to sharing future program updates,” concluded Ehrlich.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins